PharmGen Science Long-term Debt
The Long-Term Debt of PharmGen Science (004720.KS) as of Oct 28, 2026 is 205.50 M KRW. In the previous year, Long-Term Debt was 228.60 M KRW — a change of -10.10% (lower).
Get this data via API
Financial Data API
Long-term Debt
205.50 MKRW
YoY
-10.10%
Last updated:
The PharmGen Science Long-term Debt history
3 Years
10 Years
25 Years
Max
| YEAR | Long-term Debt | YoY |
|---|---|---|
| 205.50 MKRW | -10.10% | |
| 228.60 MKRW | -1.15% | |
| 231.25 MKRW | -0.73% | |
| 232.95 MKRW | -0.52% | |
| 234.17 MKRW | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
PharmGen Science Stock analysis
Frequently Asked Questions about PharmGen Science stock
Long-Term Debt of PharmGen Science is 205.50 M KRW in 2018.
Long-Term Debt of PharmGen Science changed from 228.60 M KRW to 205.50 M KRW, representing a -10.10% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Long-Term Debt PharmGen Science since 2006 – with annual values, charts, and detailed analysis.
Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.
Long-Term Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's PharmGen Science historically and in real time.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Balance Sheet — PharmGen Science
All Key Metrics — PharmGen Science
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth